Epileptic Disorders
MENUManaging Lafora body disease with vagal nerve stimulation Volume 19, issue 1, March 2017
- [Aalbers et al., 2011] Aalbers M., Vles J., Klinkenberg S., Hoogland G., Majoie M., Rijkers K. Animal models for vagus nerve stimulation in epilepsy. Exp Neurol. 2011;230:167-175.
2 - [Andrade et al., 2007] Andrade D.M., Turnbull J., Minassian B.A. Lafora disease, seizures and sugars. Acta Myol. 2007;26:83-86.
1 - [Dorr and Debonnel, 2006] Dorr A., Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J Pharmacol Exp Ther. 2006;318:890-898.
2 - [Follesa et al., 2007] Follesa P., Biggio F., Gorini G. Vagus nerve stimulation increases norepinephrine concentration and the gene expression of BDNF and bFGF in the rat brain. Brain Res. 2007;79:28-34.
11 - [Fujimoto et al., 2012] Fujimoto A., Yamazoe T., Yokota T. Clinical utility of vagus nerve stimulation for progressive myoclonic epilepsy. Seizure. 2012;21:810-812.
10 - [Groves et al., 2005] Groves D., Bowman E., Brown V. Recordings from the rat locus coeruleus during acute vagal nerve stimulation in the anaesthetized rat. Neuroscience Letters. 2005;379:174-179.
3 - [Hajnsek et al., 2013] Hajnsek S., Petelin Gadze Z., Borovecki F. Vagus nerve stimulation in Lafora body disease. Epilepsy Behav Case Rep. 2013;1:150-152.
- [Hassert et al., 2004] Hassert D., Miyashita T., Williams C. The effects of peripheral vagal nerve stimulation at a memory-modulating intensity on norepinephrine output in the basolateral amygdala. Behav Neuroscience. 2004;118:79-88.
1 - [Jansen and Andermann, 2007] Jansen AC, Andermann E. Progressive myoclonus epilepsy, Lafora type. 2007 (updated 2015 Jan 22). In: GeneReviews®. Pagon RA, Adam MP, Ardinger HH, et al. Seattle (WA): University of Washington, 1993-2016. http://www.ncbi.nlm.nih.gov/books/NBK1389/.
- [Klinkenberg et al., 2012] Klinkenberg S., Aalbers M., Vles J. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. Dev Med Child Neurol. 2012;54:855-861.
9 - [Kostov et al., 2007] Kostov H., Larsson P., Røste G. Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy? Acta Neurol Scand Suppl. 2007;115:55-58.
187 - [Krahl et al., 2003] Krahl S., Senanayake S., Handforth A. Right-sided vagus nerve stimulation reduces generalized seizure severity in rats as effectively as left-sided. Epilepsy Res. 2003;56:1-4.
1 - [Kyllerman and Ben-Menachem, 1998] Kyllerman M., Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res. 1998;29:109-114.
2 - [Lohi et al., 2007] Lohi H., Turnbull J., Zhao X. Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology. 2007;68:996-1001.
13 - [Mikati et al., 2009] Mikati M.A., Ataya N.F., El-Ferezli J.C. Quality of life after vagal nerve stimulator insertion. Epileptic Disord. 2009;11:67-74.
1 - [Minassian et al., 2016] Minassian B.A., Striano P., Avanzini G. Progressive myoclonus epilepsy: the gene-empowered era. Epileptic Disord. 2016;18:1-2.
S2 - [Monaghan and Delanty, 2010] Monaghan T., Delanty N. Lafora disease: epidemiology, pathophysiology and management. CNS Drugs. 2010;24:549-561.
7 - [Morris et al., 2013] Morris G., Gloss D., Buchhalter J., Mack K., Nickels K., Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:1453-1459.
16 - [Muñoz-Ballester et al., 2016] Muñoz-Ballester C., Berthier A., Viana R., Sanz P. Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease. Biochim Biophys Acta. 2016;1862:1074-1083.
6 - [Raedt et al., 2011] Raedt R., Clinckers R., Mollet L. Increased hippocampal noradrenaline is a biomarker for efficacy of vagus nerve stimulation in a limbic seizure model. J Neurochem. 2011;117:461-469.
3 - [Schorlemmer et al., 2013] Schorlemmer K., Bauer S., Belke M. Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease). Epilepsy Behav Case Rep. 2013;1:118-121.
- [Shbarou and Mikati, 2016] Shbarou R., Mikati M. The expanding clinical spectrum of genetic pediatric epileptic encephalopathies. Semin Pediatr Neurol. 2016;23:134-142.
2 - [Smith et al., 2000] Smith B., Shatz R., Elisevich K., Bespalova I.N., Burmeister M. Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia. 2000;41:1046-1048.
8 - [Turnbull et al., 2016] Turnbull J., Tiberia E., Striano P. Lafora disease. Epileptic Disord. 2016;18:38-62.
S2 - [Yoshimura et al., 2001] Yoshimura I., Kaneko S., Yoshimura N., Murakami T. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res. 2001;46:283-287.
3